127 related articles for article (PubMed ID: 33476574)
1. Activation of the tumor suppressive Hippo pathway by triptonide as a new strategy to potently inhibit aggressive melanoma cell metastasis.
Tan S; Zhao Z; Qiao Y; Zhang B; Zhang T; Zhang M; Qi J; Wang X; Meng M; Zhou Q
Biochem Pharmacol; 2021 Mar; 185():114423. PubMed ID: 33476574
[TBL] [Abstract][Full Text] [Related]
2. Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy.
Zhao Z; Xiang S; Qi J; Wei Y; Zhang M; Yao J; Zhang T; Meng M; Wang X; Zhou Q
Cell Death Dis; 2020 May; 11(5):387. PubMed ID: 32439835
[TBL] [Abstract][Full Text] [Related]
3. Triptonide effectively suppresses gastric tumor growth and metastasis through inhibition of the oncogenic Notch1 and NF-κB signaling pathways.
Xiang S; Zhao Z; Zhang T; Zhang B; Meng M; Cao Z; Zhou Q
Toxicol Appl Pharmacol; 2020 Feb; 388():114870. PubMed ID: 31866380
[TBL] [Abstract][Full Text] [Related]
4. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
6. Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.
Zhang B; Meng M; Xiang S; Cao Z; Xu X; Zhao Z; Zhang T; Chen B; Yang P; Li Y; Zhou Q
Biochem Pharmacol; 2019 Aug; 166():70-81. PubMed ID: 31075266
[TBL] [Abstract][Full Text] [Related]
7. Triptonide inhibits lung cancer cell tumorigenicity by selectively attenuating the Shh-Gli1 signaling pathway.
Zhang M; Tan S; Yu D; Zhao Z; Zhang B; Zhang P; Lv C; Zhou Q; Cao Z
Toxicol Appl Pharmacol; 2019 Feb; 365():1-8. PubMed ID: 30610878
[TBL] [Abstract][Full Text] [Related]
8. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
9. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
Zhang M; Meng M; Liu Y; Qi J; Zhao Z; Qiao Y; Hu Y; Lu W; Zhou Z; Xu P; Zhou Q
Breast Cancer Res; 2021 Dec; 23(1):116. PubMed ID: 34922602
[TBL] [Abstract][Full Text] [Related]
10. Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer.
Kim SH; Jin H; Meng RY; Kim DY; Liu YC; Chai OH; Park BH; Kim SM
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547587
[TBL] [Abstract][Full Text] [Related]
11. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
12. The Hippo/MST Pathway Member SAV1 Plays a Suppressive Role in Development of the Prehierarchical Follicles in Hen Ovary.
Lyu Z; Qin N; Tyasi TL; Zhu H; Liu D; Yuan S; Xu R
PLoS One; 2016; 11(8):e0160896. PubMed ID: 27505353
[TBL] [Abstract][Full Text] [Related]
13. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
14. Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
Dong F; Yang P; Wang R; Sun W; Zhang Y; Wang A; Chen M; Chen L; Zhang C; Jiang M
Prostate; 2019 Aug; 79(11):1284-1293. PubMed ID: 31212374
[TBL] [Abstract][Full Text] [Related]
15. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract][Full Text] [Related]
16. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
17. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer.
Yang H; Hu J; Chen J; Chen Z; Jiao F; Cui J; Quan M; Wang L
Med Oncol; 2020 Aug; 37(9):84. PubMed ID: 32780197
[TBL] [Abstract][Full Text] [Related]
19. Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment.
Gao B; Chen J; Han B; Zhang X; Hao J; Giuliano AE; Cui Y; Cui X
Sci Rep; 2021 Jan; 11(1):2408. PubMed ID: 33510281
[TBL] [Abstract][Full Text] [Related]
20. Targeting of multiple senescence-promoting genes and signaling pathways by triptonide induces complete senescence of acute myeloid leukemia cells.
Pan Y; Meng M; Zheng N; Cao Z; Yang P; Xi X; Zhou Q
Biochem Pharmacol; 2017 Feb; 126():34-50. PubMed ID: 27908660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]